News

Fredun Pharmaceuticals Ltd share price ticked higher by 3.33% to Rs 1547.75 after the company`s net profit surged by 21.80% to Rs 13.13 crore, while revenue from operations slightly gained 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.4 lakh crore, rising 4.13%. It has improved by 0.06% over last one week and advanced by 9.58% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 27.07% and 96.33% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, expanding by 127.32% year-on-year, and jumping 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, rallying 92.70% YoY and improving 13.37% sequentially. Total expenses posted a minor rise of 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, posting a minor increase of 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, collapsing by 19.64% YoY. For the TTM ended FY26, revenue from operations soared by 40.21% to Rs 633.33 crore, while net profit saw a strong growth of 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 5712% to Rs 94.54 crore, and PBT soared 70.97% to Rs 47.0 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 343.42% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.

Fredun Pharmaceuticals Limited reported no deviation or variation in the utilization of Rs 111.53 crore raised through a preferential issue during the quarter ended June 30, 2026, according to a regulatory filing. The company, in a statement filed with the BSE Limited, acknowledged observations from the Monitoring Agency, Care Ratings Limited, regarding the classification of certain expenditures and reconciliation of unutilized proceeds, but maintained that these did not constitute a deviation from the originally stated objects for which the funds were raised.

Net profit of Fredun Pharmaceuticals rose 93.94% to Rs 13.13 crore in the quarter ended June 2026 as against Rs 6.77 crore during the previous quarter ended June 2025. Sales rose 90.75% to Rs 227.76 crore in the quarter ended June 2026 as against Rs 119.40 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales227.76119.40 91 OPM %14.3714.23 - PBDT24.1210.46 131 PBT20.559.04 127 NP13.136.77 94 Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Fredun Pharmaceuticals announced that the 39th Annual General Meeting(AGM) of the company will be held on 30 June 2026.